单磷酸阿糖腺苷治疗手足口病126例疗效观察
单磷酸阿糖腺苷治疗手足口病126例疗效观察
【摘要】 目的观察单磷酸阿糖腺苷治疗手足口病的临床疗效。方法 252例手足口病患儿随机分为治疗组与对照组各126例。治疗组采用单磷酸阿糖腺苷治疗,5~10 mg/(kg•d)加入5%葡萄糖液或10%葡萄糖液(稀释浓度0.1%)静脉滴注1次/d,治疗5~10 d。对照组采用利巴韦林治疗10~15 mg/(kg•d)静脉滴注1次/d,治疗5~10 d,比较两组的疗效及不良反应。结果 治疗组总有效率96.82%,对照组84.13%,两组比较,差异具有统计学意义(P<0.05),两组均未见明显不良反应。结论 单磷酸阿糖腺苷治疗手足口病的临床疗效好。
【Abstract】 Objective Ara-AMP treatment efficacy for HFMD. Methods 252 cases of child patients with HFMD were randomly divided into treatment group and control group of 126 cases. Treatment group were treated Ara-AMP, 5 ~ 10 mg/(kg•d) 5% glucose solution or 10% glucose solution (dilution of 0.1%) intravenous infusion of 1 day, 5 to 10 days treatment. Control group treated with ribavirin 10 ~ 15 mg/(kg•d) intravenously one time a day, treatment 5 to 10 days, two groups were compared the efficacy and adverse reactions. Results The total effective rate was 96.82%. Control group was 84.13%, the difference was statistically significant (P<0.05), the two groups an had no significant adverse reactions. Conclusion Ara-AMP treatment of the disease has a good clinical efficacy.
【Key words】 Children; Hand foot and mouth disease; Ara-adenosine
手足口病(HFMD)是由多种肠道病毒包括肠道病毒71型(EV71)和柯萨奇病毒A组(CoXA)、埃可病毒(Echo)的某些血清型等引起的常见以皮肤病变为其特征的传染病,以婴幼儿发病为主。大多数患者症状轻微,以发热和手、足、口腔等部位的皮疹或疱疹为主要特征[1]。少数患者可并发无菌性脑膜炎、脑炎、急性弛缓性麻痹、呼吸道感染和心肌炎,个别重症患儿病程进展快,易发生死亡[2]。2008年1月至2009年12月20081-200912年来我院门诊就诊患者采用单磷酸阿糖腺苷治疗,现报告如下。
1 资料与方法
1.1 一般资料 本组患儿共252例,均符合手足口病诊断标准。按数学随机法分为治疗组和对照组各126例,治疗组,男76例,女50例,年龄8个月~8岁,病程3~19 d,其中并发肺炎26例,脑炎、心肌炎各2例。对照组,男72例,女54例,8个月~8岁,病程3~19 d,其中并发肺炎20例,心肌炎2例[3]。两组的性别、年龄、病程等资料比较,差异无统计学意义,具有可比性。
1.2 治疗方法 治疗组给予单磷酸阿糖腺苷5~10 mg/(kg•d)加入5%葡萄糖液或10%葡萄糖液(稀释浓度0.1%)静脉滴注(不可与含钙的输液配伍),1次/d,5~10 d为1个疗程治疗,合并感染时加用抗生素治疗。对照组给予利巴韦林